101. Sugar-coated liposomes: a novel delivery system for increased drug efficacy and reduced drug toxicity.
- Author
-
Medda S, Mukherjee S, Das N, Naskar K, Mahato SB, and Basu MK
- Subjects
- Animals, Antiprotozoal Agents therapeutic use, Antiprotozoal Agents toxicity, Cricetinae, Disease Models, Animal, Drug Carriers, Drug Compounding, Glucose chemistry, Liver drug effects, Liver enzymology, Macrophages drug effects, Male, Mannose chemistry, Mesocricetus, Mice, Organometallic Compounds therapeutic use, Organometallic Compounds toxicity, Urea administration & dosage, Urea therapeutic use, Urea toxicity, Antiprotozoal Agents administration & dosage, Glycosides chemistry, Leishmaniasis, Visceral drug therapy, Liposomes chemistry, Macrophages metabolism, Organometallic Compounds administration & dosage, Urea analogs & derivatives
- Abstract
The uptake of glycoside-bearing liposomes by macrophages has been studied in vitro. Since the uptake was found to be specific for the end sugar attached to the glycoside, the possibility is raised that glycoside-bearing liposomes might be used in vivo as systems to deliver drugs to macrophages. Using the antileishmanial drug urea stibamine, these delivery systems have been tested in vivo against model leishmaniasis. The results indicate that the drug encapsulated in sugar-coated liposomes is much more potent in comparison with normal liposome-encapsulated drug or to the free drug. Mannose-grafted liposomes are more efficient in transportation of drugs compared with those bearing glucose. Toxicity studies involving blood parameters, histological staining of tissues and specific enzyme activities related to liver function, show no apparent toxicity with the drugs. Hence, drug encapsulated sugar-coated liposomes may have possible applications to humans.
- Published
- 1993